HK Stock Market Move | HENLIUS (02696) rises over 5%, self-developed KAT6A/B small molecule inhibitor HLX97 obtains IND approval from the National Medical Products Administration.
Furui Holdings (02696) rose more than 5%, as of the writing, rose by 5.02%, to HK$68, with a turnover of HK$1948.15 million.
HENLIUS (02696) rose by more than 5%, as of the time of writing, it rose by 5.02% to HKD 68, with a turnover of HKD 194.815 million.
On the news front, on March 5, HENLIUS announced that its independently developed HLX97 (KAT6A/B small molecule inhibitor) had received approval from the National Medical Products Administration (NMPA) for Phase I clinical trial application in patients with advanced/metastatic solid tumors. HLX97 is a small molecule inhibitor of lysine acetyltransferase 6A/B (KAT6A/B) developed by the company itself, intended for the treatment of advanced/metastatic solid tumors. Preclinical studies have shown that HLX97 can inhibit the activity of KAT6A/B, demonstrating good anti-tumor efficacy and safety characteristics.
As of the date of this announcement, there have been no approved KAT6A/B small molecule inhibitors on the market worldwide.
Related Articles
On March 5th, MNSO(09896) spent approximately $231,200 to repurchase around 55,600 shares.
WASION HOLDINGS (03393) predicts a net profit of approximately 1 billion to 1.06 billion yuan in 2025, an increase of about 42% to 50% year-on-year.
SSY GROUP (02005) has obtained the drug production registration approval for the attention to the use of Calcium Levofolinate (25mg).
On March 5th, MNSO(09896) spent approximately $231,200 to repurchase around 55,600 shares.
WASION HOLDINGS (03393) predicts a net profit of approximately 1 billion to 1.06 billion yuan in 2025, an increase of about 42% to 50% year-on-year.
SSY GROUP (02005) has obtained the drug production registration approval for the attention to the use of Calcium Levofolinate (25mg).
RECOMMEND
